Erin Flynt, Ph.D.
Executive Director, Translational Medicine
Erin is the Executive Director of Translational Medicine at K36. She brings 15 years of hematology/oncology experience in disease biology and patient segmentation.
Her career started at Precept Medical Communications, where she became Medical Director, before moving to Envision Communications and becoming Director of Scientific Strategy. Following these roles, she led large-scale strategic projects, including the Myeloma Genome Project, as Scientific Senior Director of Myeloma Disease at Celgene and Bristol Myers Squibb. Here, she focused on multiple myeloma disease, translational strategy, execution, and scientific communication.
Erin earned her BS in Biochemistry and Molecular Biology at the University of Georgia. In addition, she completed her Ph.D. and post doc research fellowship at Vanderbilt University.